Search clinical trials for: Aldesleukin (IL-2)

Total 16667 results

Beth Israel Deaconess Medical Center
Dana-Farber Cancer Institute

Completed

IL-2 "SELECT" Tissue Collection Protocol in Patients With Advanced Melanoma

Malignant Melanoma

United States
Centre Hospitalier Universitaire de Nīmes

Completed

Immuno-modulation in Amyotrophic Lateral Sclerosis- a Phase II Study of Safety and Activity of Low Dose Interleukin-2 (IMODALS)

Amyotrophic Lateral Sclerosis

France
National Institute of Allergy and Infectious Diseases...
Chiron Corporation

Completed

Effect of Intermittent Aldesleukin Treatment With or Without Anti-HIV Drugs in HIV Infected People (STALWART)

HIV Infections

United States, Australia, Argentina, Morocco, Portugal, Thailand, Chile, Italy, Poland, Spain, United Kingdom
Jay S. Skyler
University of Florida; University of California, San Francisco; Diabetes Research...

Withdrawn

Low-dose IL-2 in Established T1D - The "PROREG" Study

Diabetes | Diabetes Mellitus, Type 1 | Diabetes, Autoimmune

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Aerosolized Aldesleukin in Treating Patients With Lung Metastases

Sarcoma | Metastatic Melanoma | Metastatic Renal Cell Cancer | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Stage IV Osteosarcoma AJCC v7 | Metastatic Osteosarcoma | Stage IV Renal Cell Cancer AJCC v7 | Metastatic Malignant Neoplasm in the Lung

United States
Alaunos Therapeutics

Active, not recruiting

Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors

Gynecologic Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Cholangiocarcinoma | Adenocarcinoma of Lung | Endometrial Cancer | Non-small Cell Lung Cancer | Ovarian Carcinoma | Squamous Cell Lung Cancer | Ovary Neoplasm | Adenosquamous Cell Lung Cancer

United States
Northwestern University
National Cancer Institute (NCI)

Completed

Pilot Study of Denileukin Diftitox Plus High-Dose IL-2 for Patients With Metastatic Renal Cancer

Kidney Cancer

United States
Cambridge University Hospitals NHS Foundation Trust
Juvenile Diabetes Research Foundation; Wellcome Trust; University of Cambridge; National Institute for Health Research, United Kingdom and other collaborators

Completed

Adaptive Study of IL-2 Dose Frequency on Regulatory T Cells in Type 1 Diabetes (DILfrequency)

Type 1 Diabetes

United Kingdom
Istituto Giannina Gaslini

Completed

IL-2 for Multi Drug Resistant Nephrotic Syndrome

Nephrotic Syndrome

Italy
Anil K. Chandraker, MD

Terminated

Ultra-low Dose Subcutaneous IL-2 in Renal Transplantation

Kidney Transplantation

United States
Case Western Reserve University

Terminated

HIV Reservoir Reduction With Interleukin-2 (IL2)

HIV Infection

United States
National Institute of Allergy and Infectious Diseases...

Completed

Effectiveness of Interleukin-2 (IL-2) Plus Anti-HIV Therapy in HIV-Positive Patients

HIV Infections

United States
Brigham and Women's Hospital

Terminated

Novel Strategies to Improve Immunomodulation and Non-invasive Clinical Monitoring in VCA

Abdominal Wall Defect | Amputation, Traumatic | Amputation;Traumatic;Old | Face Injury | Face; Deformity

United States
Peking University People's Hospital

Unknown

The Incidence of Infection in Treatment of Low-dose IL-2 of SLE Patients

Infection

China
Peking University Third Hospital

Recruiting

Low Dose IL-2 in the Treatment of Immune-associated ALS Syndrome

Amyotrophic Lateral Sclerosis

China
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Interleukin-2 in Treating Children Who Have Undergone Bone Marrow Transplantation for Acute Myeloid Leukemia

Leukemia

United States, Switzerland, Canada, Netherlands, Puerto Rico, Australia
National Institute of Allergy and Infectious Diseases...
ANRS, Emerging Infectious Diseases

Completed

Phase II/III Study Evaluating the Effect of IL-2 on Preservation of the CD4 T-Lymphocytes After Interruption of Antiretroviral Treatment in HIV-Infected Patients With CD4 T-Lymphocyte Count Greater Than 500 Cells/mm3 Who Received Antiretroviral Tx (ILIADE)

HIV Infections

United States, France
Providence Health & Services
Prometheus Laboratories; Cytokine Working Group

Active, not recruiting

Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer

Renal Cell Carcinoma

United States
NeogenTC

Not yet recruiting

TIL Therapy for Patients With Advanced Solid Tumors

Advanced Breast Cancer | Advanced Lung Cancer
Radboud University Medical Center
Dutch Cancer Society

Recruiting

Natural Killer-cell Therapy for Acute Myeloid Leukemia (NK4AML)

Acute Myeloid Leukemia Refractory | Acute Myeloid Leukemia, Relapsed, Adult

Netherlands
Groupe Francophone des Myelodysplasies
EpiCept Corporation

Withdrawn

Azacitidine With or Without Ceplene/Interleukin-2 in Patients With Higher Risk Myelodysplastic Syndromes

Myelodysplastic Syndromes

France
Masonic Cancer Center, University of Minnesota

Completed

Radiation and Combination Immunotherapy for Melanoma

Metastatic Melanoma

United States
jiangjingting

Unknown

Anti-CD19:TCRζ Chimeric Antigen Receptor-T Cells in the Treatment for CD19+ B Cell Lymphoma

Lymphoma, B Cell

China
Roger Williams Medical Center

Terminated

Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and GM-CSF in Treating Patients With Recurrent, Refractory, or Metastatic Non-Small Cell Lung Cancer

Lung Cancer

United States
University of Chicago

Terminated

Trial of G250 Peptide and IL-2 Following Surgical Resection of Locally Advanced/Metastatic Renal Cell Carcinoma

Metastatic Renal Cell Carcinoma

United States
National Cancer Institute (NCI)

Completed

Immunization of Patients With Metastatic Melanoma Using the GP100 Peptide Preceded by an Endoplasmic Reticulum Insertion Signal Sequence

Melanoma | Neoplasm Metastasis

United States
Dartmouth-Hitchcock Medical Center
National Cancer Institute (NCI)

Completed

Cyclophosphamide, Fludarabine, and High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Leukemia After Undergoing Donor Stem Cell Transplant

Recurrent Adult Acute Myeloid Leukemia | Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult... and other conditions

United States
Masonic Cancer Center, University of Minnesota

Terminated

Phase II Study of Allo LMI Vaccine With IL-2 for Stable Metastatic Breast Ca

Breast Cancer

United States
University of Minnesota

Completed

Adoptive Transfer of Haploidentical Natural Killer Cells and IL-2

HIV

United States
University of California, Davis

Completed

UCDCC#269: A Pilot Study of Interlesional IL-2 and RT in Patients With NSCLC.

METASTATIC NON-SMALL CELL LUNG CANCER

United States
National Cancer Institute (NCI)

Completed

A Randomized Study of EPOCH II Versus EPOCH II and Immunotherapy in Lymphomas

Non Hodgkin's Lymphoma | Hodgkin's Disease

United States
National Cancer Institute (NCI)

Terminated

Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer

Metastatic Melanoma | Metastatic Renal Cancer

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Vaccine Therapy and GM-CSF With or Without Low-Dose Aldesleukin in Treating Patients With Stage II, Stage III, or Stage IV Melanoma

Melanoma (Skin)

United States
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI); National Institutes of Health (NIH); Chiron...

Completed

Sequential ATRA Then IL-2 for Modulation of Dendritic Cells and Treatment of Metastatic Renal Cell Cancer

Kidney Cancer

United States
National Cancer Institute (NCI)

Terminated

Interleukin-12 and Interleukin-2 in Treating Patients With Refractory or Recurrent Neuroblastoma

Recurrent Neuroblastoma

United States
National Cancer Institute (NCI)

Terminated

Combination Therapy of Interleukin-12 and Interleukin-2 to Treat Advanced Cancer

Sarcoma | Breast Neoplasm | Lung Neoplasm | Kidney Neoplasm

United States
Assistance Publique - Hôpitaux de Paris
Iltoo Pharma

Completed

Low-dose IL-2 to the Kinetics of Regulatory T-cell in Healthy Volunteers (HEALTHIL-2)

Healthy Volunteers

France
Masonic Cancer Center, University of Minnesota

Completed

Aldesleukin With or Without Vaccine Therapy in Treating Patients With Stage IV Melanoma

Stage IV Melanoma

United States
Gregory Knapp

Not yet recruiting

Efficacy of Interleukin-2 in Triple Negative Breast Cancer

Triple Negative Breast Cancer
The Methodist Hospital Research Institute
Massachusetts General Hospital; The Center for Clinical and Translational Sciences... and other collaborators

Active, not recruiting

T-regulatory Cells in ALS (Tregs in ALS)

ALS (Amyotrophic Lateral Sclerosis)

United States
Iovance Biotherapeutics, Inc.

Active, not recruiting

Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
University of Virginia
National Cancer Institute (NCI)

Unknown

Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma

Recurrent Neuroblastoma | Disseminated Neuroblastoma

United States
National Cancer Institute (NCI)

Completed

Interleukin-2 and Bryostatin 1 in Treating Patients With Advanced Kidney Cancer

Stage III Renal Cell Cancer | Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer

United States
Dana-Farber Cancer Institute
The Leukemia and Lymphoma Society

Active, not recruiting

CIML NK Cells With Venetoclax for AML

Acute Myeloid Leukemia | Leukemia | Leukemia, Myeloid | Acute Myeloid Leukemia Recurrent

United States
National Cancer Institute (NCI)

Completed

Vaccine Plus Interleukin-2 in Treating Patients With Advanced Melanoma

Recurrent Melanoma | Stage IV Melanoma

United States
National Institute of Allergy and Infectious Diseases...
Chiron Corporation

Completed

An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy (ESPRIT)

HIV Infections

United States, Brazil, Australia, Argentina, Austria, Belgium, Canada, Denmark, France, Germany, Ireland, Israel, Italy, Japan, Morocco, Netherlands, Norway, Poland, Portugal, Singapore, Spain, Sweden, Switzerland, Thailand, United Kingdom
National Cancer Institute (NCI)

Terminated

Interleukin-12 and Interleukin-2 in Treating Patients With Mycosis Fungoides

Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma | Recurrent Mycosis Fungoides/Sezary Syndrome | Stage III Cutaneous T-cell Non-Hodgkin Lymphoma | Stage III Mycosis Fungoides/Sezary Syndrome | Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma | Stage IV Mycosis Fungoides/Sezary Syndrome | Stage I... and other conditions

United States
National Cancer Institute (NCI)

Completed

Interleukin-12 Plus Interleukin-2 in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Oxford BioMedica
The Methodist Hospital Research Institute; ORION Clinical Services

Completed

Safety and Biological Activity of TroVax® Vaccine Given With IL-2 in Renal Cell Carcinoma

Carcinoma, Renal Cell

United States

Search clinical trials for: Aldesleukin (IL-2)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in El Salvador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations